Bristol-Myers Squibb Launches Biologic Autoinjector for Rheumatoid Arthritis

Orencia ClickJect Autoinjector has an ergonomic design that may be beneficial for patients.

Bristol-Myers Squibb recently announced that they will launch Orencia (abatacept) ClickJect Autoinjector for the treatment of moderate-to-severe rheumatoid arthritis (RA).

This biologic drug has already been approved by the FDA in the form of an IV infusion, prefilled syringe, and autoinjector. Orencia ClickJect delivers the medication subcutaneously with push button operation and injection confirmation.

This system may reduce user errors, according to a press release from Bristol-Myers Squibb.

“Rheumatoid arthritis often affects joints in the hand and impairs dexterity,” said Sheila Kelly, MD, US Orencia medical lead, Bristol-Myers Squibb. “Through the new Orencia ClickJect, we are able to offer the proven benefits of ORENCIA in an accurate dose self-injection and provide an additional option for healthcare providers when selecting treatment options for their patients.”

The Orencia ClickJect offers an ergonomic design and no slip-grip. It also has a large window and indicator to show the patient that their full dose has been injected.

Patients only need to hold down the button for 15 seconds before the dose is administered. It has a transparent tip that locks around the needle after injection to prevent accidental sticks, according to the press release.

Orencia is indicated to reduce the signs and symptoms in adults with moderate-to-severe RA. It should not be administered with tumor necrosis factor antagonists or other biologic RA drugs.

Orencia ClickJect was evaluated based on comfort, control, ease of use, and confidence of dose, according to the press release.

The most common adverse effects were headache, upper respiratory tract infection, nasopharyngitis, and nausea.

“Today’s launch of the Orencia ClickJect is an example of our continued commitment to offering patients with moderate-to-severe rheumatoid arthritis a treatment option that may be appropriate for them, now available as an autoinjector,” said Chris Boerner, head of US Commercial, Bristol-Myers Squibb. “This approval offers more options for healthcare providers and members of the arthritis community to consider when selecting the optimal treatment and administration option for each individual.”